Table 1

Mean glucose versus HbA1c in subgroups

Slope for mean glucose versus HbA1c (mg/dL per 1%)
Subjects (n)*3 months2 months1 month
Overall25224.4 ± 2.325.4 ± 2.425.7 ± 2.9
Age (years)
 8–145425.0 ± 3.726.3 ± 4.126.6 ± 4.9
 15–246024.6 ± 4.825.1 ± 5.326.3 ± 6.9
 ≥2513820.7 ± 3.521.8 ± 3.620.9 ± 4.1
Treatment group
 Control12222.5 ± 3.724.2 ± 4.022.8 ± 4.8
 RT-CGM13025.7 ± 2.926.1 ± 3.127.9 ± 3.6
Sex
 Female13724.8 ± 3.025.8 ± 3.225.9 ± 3.9
 Male11523.5 ± 3.624.5 ± 3.825.0 ± 4.5
Insulin delivery
 Multiple daily injections4225.8 ± 6.026.8 ± 6.129.3 ± 8.0
 Pump21023.5 ± 2.524.3 ± 2.724.0 ± 3.2
CGM device
 DexCom5325.8 ± 4.927.5 ± 5.329.5 ± 7.2
 Navigator5220.7 ± 4.322.0 ± 4.821.1 ± 5.8
 Paradigm14724.8 ± 3.325.4 ± 3.425.4 ± 3.8
Change in HbA1c over the prior 3 months
 Improved ≥0.5%2626.4 ± 5.725.3 ± 5.725.2 ± 6.4
 Within ±0.4%19524.2 ± 3.024.6 ± 3.225.5 ± 3.8
 Worsened ≥0.5%3125.7 ± 5.827.1 ± 6.123.6 ± 7.5
  • Data are slopes (± margin of error for 95% CI) unless otherwise indicated.

  • *One subject was not included in the 1-month analysis because of insufficient data.

  • †Mean glucose calculated from CGM data taken over 3 months (91 days), 2 months (61 days), and 1 month (30 days) before the HbA1c measurement. To convert slopes to mmol/L per 1%, divide by 18. RT-CGM, real-time continuous glucose monitoring.